NeoStem subsidiary enters into services agreement with IRX Therapeutics NeoStem and its subsidiary, Progenitor Cell Therapy, announced the execution of a Services Agreement with IRX Therapeutics, under which PCT will provide services to support IRX's development of IRX-2, a primary cell-derived biologic with multiple active cytokine components. IRX-2 is a cancer therapeutic designed to activate a patient's immune system to broadly restore immunity and overcome cancer-induced immune suppression. IRX has engaged PCT for the manufacture of an intermediate component referred to as IRX-2 Drug Substance for human clinical trials.
News For NBS From The Last 14 Days
Check below for free stories on NBS the last two weeks.